S&P 500   4,508.44 (+0.49%)
DOW   35,379.08 (+0.34%)
QQQ   374.01 (+0.36%)
AAPL   148.12 (+1.07%)
MSFT   308.64 (+0.44%)
FB   338.11 (+0.83%)
GOOGL   2,862.55 (+0.24%)
TSLA   864.11 (-0.69%)
AMZN   3,438.00 (-0.25%)
NVDA   220.79 (-0.64%)
BABA   172.71 (+3.53%)
NIO   40.20 (+1.49%)
CGC   13.35 (+1.14%)
GE   104.22 (+0.10%)
AMD   114.90 (-1.31%)
MU   67.06 (-0.30%)
T   25.43 (+0.39%)
F   15.54 (-0.13%)
ACB   6.97 (+0.72%)
DIS   170.94 (-0.12%)
PFE   41.92 (+1.45%)
BA   216.07 (-0.42%)
AMC   43.44 (+0.95%)
S&P 500   4,508.44 (+0.49%)
DOW   35,379.08 (+0.34%)
QQQ   374.01 (+0.36%)
AAPL   148.12 (+1.07%)
MSFT   308.64 (+0.44%)
FB   338.11 (+0.83%)
GOOGL   2,862.55 (+0.24%)
TSLA   864.11 (-0.69%)
AMZN   3,438.00 (-0.25%)
NVDA   220.79 (-0.64%)
BABA   172.71 (+3.53%)
NIO   40.20 (+1.49%)
CGC   13.35 (+1.14%)
GE   104.22 (+0.10%)
AMD   114.90 (-1.31%)
MU   67.06 (-0.30%)
T   25.43 (+0.39%)
F   15.54 (-0.13%)
ACB   6.97 (+0.72%)
DIS   170.94 (-0.12%)
PFE   41.92 (+1.45%)
BA   216.07 (-0.42%)
AMC   43.44 (+0.95%)
S&P 500   4,508.44 (+0.49%)
DOW   35,379.08 (+0.34%)
QQQ   374.01 (+0.36%)
AAPL   148.12 (+1.07%)
MSFT   308.64 (+0.44%)
FB   338.11 (+0.83%)
GOOGL   2,862.55 (+0.24%)
TSLA   864.11 (-0.69%)
AMZN   3,438.00 (-0.25%)
NVDA   220.79 (-0.64%)
BABA   172.71 (+3.53%)
NIO   40.20 (+1.49%)
CGC   13.35 (+1.14%)
GE   104.22 (+0.10%)
AMD   114.90 (-1.31%)
MU   67.06 (-0.30%)
T   25.43 (+0.39%)
F   15.54 (-0.13%)
ACB   6.97 (+0.72%)
DIS   170.94 (-0.12%)
PFE   41.92 (+1.45%)
BA   216.07 (-0.42%)
AMC   43.44 (+0.95%)
S&P 500   4,508.44 (+0.49%)
DOW   35,379.08 (+0.34%)
QQQ   374.01 (+0.36%)
AAPL   148.12 (+1.07%)
MSFT   308.64 (+0.44%)
FB   338.11 (+0.83%)
GOOGL   2,862.55 (+0.24%)
TSLA   864.11 (-0.69%)
AMZN   3,438.00 (-0.25%)
NVDA   220.79 (-0.64%)
BABA   172.71 (+3.53%)
NIO   40.20 (+1.49%)
CGC   13.35 (+1.14%)
GE   104.22 (+0.10%)
AMD   114.90 (-1.31%)
MU   67.06 (-0.30%)
T   25.43 (+0.39%)
F   15.54 (-0.13%)
ACB   6.97 (+0.72%)
DIS   170.94 (-0.12%)
PFE   41.92 (+1.45%)
BA   216.07 (-0.42%)
AMC   43.44 (+0.95%)
NASDAQ:NBEV

NewAge Stock Forecast, Price & News

$1.44
+0.03 (+1.76 %)
(As of 10/19/2021 10:10 AM ET)
Add
Compare
Today's Range
$1.44
$1.45
50-Day Range
$1.37
$2.27
52-Week Range
$1.35
$4.55
Volume534 shs
Average Volume1.69 million shs
Market Capitalization$197.66 million
P/E RatioN/A
Dividend YieldN/A
Beta1.13
30 days | 90 days | 365 days | Advanced Chart
Receive NBEV News and Ratings via Email

Sign-up to receive the latest news and ratings for NewAge and its competitors with MarketBeat's FREE daily newsletter.


NewAge logo

About NewAge

NewAge Inc is engaged in the business of developing, marketing, selling, and distributing a portfolio of healthy products. It offers a portfolio of healthy products with its brands across platforms, such as health & wellness, inner & outer beauty, and nutrition & weight management. Its partner companies include ARIIX, Noni, LIMU, and ZENNOA. The company was founded by Neil Fallon on April 26, 2010 and is headquartered in Denver, CO.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Malt beverages
Sub-Industry
N/A
Current Symbol
NASDAQ:NBEV
Employees
1,109
Year Founded
N/A

Sales & Book Value

Annual Sales
$279.47 million
Book Value
$1.19 per share

Profitability

Net Income
$-39.34 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$197.66 million
Next Earnings Date
11/8/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

1.65 out of 5 stars

Consumer Staples Sector

125th out of 181 stocks

Malt Beverages Industry

5th out of 6 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












NewAge (NASDAQ:NBEV) Frequently Asked Questions

Is NewAge a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NewAge in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NewAge stock.
View analyst ratings for NewAge
or view top-rated stocks.

What stocks does MarketBeat like better than NewAge?

Wall Street analysts have given NewAge a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NewAge wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting NewAge?

NewAge saw a increase in short interest in August. As of August 31st, there was short interest totaling 7,350,000 shares, an increase of 21.5% from the August 15th total of 6,050,000 shares. Based on an average daily volume of 1,050,000 shares, the short-interest ratio is presently 7.0 days. Currently, 5.5% of the shares of the stock are short sold.
View NewAge's Short Interest
.

When is NewAge's next earnings date?

NewAge is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for NewAge
.

How were NewAge's earnings last quarter?

NewAge, Inc. (NASDAQ:NBEV) released its quarterly earnings data on Monday, August, 9th. The company reported ($0.19) EPS for the quarter, missing the Zacks' consensus estimate of ($0.02) by $0.17. The business had revenue of $124.04 million for the quarter, compared to analyst estimates of $127.71 million. NewAge had a negative net margin of 4.61% and a negative trailing twelve-month return on equity of 19.36%.
View NewAge's earnings history
.

How has NewAge's stock price been impacted by COVID-19?

NewAge's stock was trading at $1.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NBEV stock has decreased by 16.0% and is now trading at $1.4450.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for NBEV?

2 brokerages have issued 12 month target prices for NewAge's stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate NewAge's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 315.2% from the stock's current price.
View analysts' price targets for NewAge
or view top-rated stocks among Wall Street analysts.

Who are NewAge's key executives?

NewAge's management team includes the following people:
  • Brent David Willis, Chief Executive Officer & Director
  • Mark Wilson, Group President
  • Phil Lewis, Senior Vice President-Operations
  • Kevin Manion, Chief Financial Officer
  • Blake Heringer, Chief Information Officer

What other stocks do shareholders of NewAge own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NewAge investors own include (CGC), Aurora Cannabis (ACB), Tilray (TLRY), Cronos Group (CRON), Advanced Micro Devices (AMD), Micron Technology (MU), NIO (NIO), BHP Group (BHP), (APHA) and General Electric (GE).

What is NewAge's stock symbol?

NewAge trades on the NASDAQ under the ticker symbol "NBEV."

How do I buy shares of NewAge?

Shares of NBEV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NewAge's stock price today?

One share of NBEV stock can currently be purchased for approximately $1.45.

How much money does NewAge make?

NewAge has a market capitalization of $197.66 million and generates $279.47 million in revenue each year. The company earns $-39.34 million in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does NewAge have?

NewAge employs 1,109 workers across the globe.

What is NewAge's official website?

The official website for NewAge is newagebev.us.

Where are NewAge's headquarters?

NewAge is headquartered at 2420 17TH STREET SUITE 220, DENVER CO, 80202.

How can I contact NewAge?

NewAge's mailing address is 2420 17TH STREET SUITE 220, DENVER CO, 80202. The company can be reached via phone at (303) 566-3030 or via email at [email protected].


This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.